Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
At Boehringer Ingelheim we are giving patients new hope. We are collaborating with the oncology community on a shared journey to deliver leading science.
Lead Patient Safety Physician Maria Weber tells us about why she joined Boehringer Ingelheim, and the importance of patient centricity in everything she does.